![]()
![]()
![]()
Recently, the well-known industry media Endpoints News released the “Top 25 CEO Compensation List in the Biopharmaceutical Industry for 2025,” with the entry threshold raised to$25 million。Meanwhile,Endpoints A statistical analysis was conducted on the compensation of CEOs from 448 publicly listed life sciences companies with market capitalizations exceeding $100 million. The results showed that,2025 CEO Compensation in the Biopharmaceutical IndustryThe median reached US$5.35 million, a year-on-year increase of 13%,The average compensation is $8.8 million., a year-on-year increase of 34%.Top 25 List, outhave seen the emergence of many innovative biotech companies, such asSummit, which licensed Akeso’s ivonescimab, and Vor, which partnered with RemeGen on telitacicept, dedicated to the development of novel ophthalmic drugsOcular, etc. Additionally, the CEOs of Eli Lilly, Johnson & Johnson, AbbVie, Gilead, and Pfizer also successfully made the list.Source: Foreign media, compiled by InsightThis article provides a detailed overview of the compensation packages for the top five CEOs on the list, for reference.Summit has sparked a global surge in the development of PD-1/VEGF bispecific antibodies, leveraging ivonescimab licensed from Akeso.As Co-CEO of the company, Maky Zanganeh received $246 million in compensation in 2025.。This is mainly because in April 2025,Summit Board of DirectorsAmended legacy stock options, making it more valuable.Zanganeh held approximately 11 million of such options, which were originally subject to performance-based vesting. The Board of Directors decided to change them to time-based vesting only, thereby increasing the fair value of these options from approximately $15 million to $245 million.No, also serving as Co-CEOBob Duggan’s compensation amounted to only $172,376, representing the value of equity awards he received as a director of Summit.As in previous years, Duggan declined compensation for the role of co-CEO.(According to Summit documents, Duggan holds more than 570 million shares of Summit stock, accounting for 73.5% of the company, with this stake now valued at $8.4 billion.)2025,Marc Casper received nearly $80 million in compensation, including a one-time equity grant of $57.7 millionAdminister.Thermo Fisher Scientific’s Compensation Committee stated that this was toLetMarc Casper to Remain in Position Until 2030, the conditions for obtaining these shares depend on the company’s stock price performance relative to the S&P 500 Index over the next ten years.Interestingly,Marc Casper’s compensation package has been rejected by shareholders for two consecutive years. However, the vote on executive pay is non-binding and is unlikely to affectMarc Casper's Compensation.Vor Biopharma
Jean-Paul Kress
Vor Biopharma underwent a major strategic pivot in 2025, gradually winding down its cancer cell therapy operations, andLicensed a new core drug project, Telitacicept, from RemeGen。Jean-Paul Kress joined the company at this very moment.KresS’s compensation consisted almost entirely of 4.16 million stock options granted in June, valued at $64 million. Additionally, last December,Vor The Board of Directors decided to reprice these options, reducing the exercise price from $17.80 to $8.18.Vor spokesperson stated,Kress was responsible for the company’s comprehensive restructuring, including recruiting nearly 100 employees and raising $570 million. His compensation reflects both the demands of this mandate and its alignment with long-term shareholder value creation.KKevin Conroy Serves as Leader in Early Colorectal Cancer Screening GiantCEO of Exact Sciences, with over ten years of experience. March 2025,Healthcare Giant Abbott Acquires Exact for $23 Billion, ending Conroy's tenure.Conroy’s 2025 compensation package included $21.2 million in stock awards, as well as nearly $25 million in value derived from a tax-reduction strategy implemented prior to Abbott’s acquisition.In December 2024, the Exact Board of Directors in advance to ConroyBonuses and partial stock awards were distributed with the aim of circumventing the U.S. Internal Revenue Service.（IRS）Tax Implications of Section 280G. This provision aims to deter the payment of excessive amounts to executives in merger and acquisition transactions by imposing an excise tax.Keenova Therapeutics
Sigurdur Olafsson
Keenova is a specialty pharmaceutical company formed after the merger of Mallinckrodt and Endo. In 2025, the company paid Sigurdur Olafsson$34.4 million prize, which is related to the sale of its medical device division, Therakos, in 2024. That divestiture helpedMallinckrodt’s control of high debt levels also paved the way for its merger with Endo.
In July 2025, following the completion of the Endo merger, he received a compensation package: a one-time cash payment of $6 million if he continued to serve as Chief Executive Officer until January 2027.
Cover source:Corporate Logo / Stocksy UnitedDisclaimer:This article is for informational purposes only and does not represent the stance or views of Insight, nor does it constitute recommendations or introductions to treatment plans. If needed, please consult and contact legitimate medical institutions.
